TWO SIGMA ADVISERS, LP - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 117 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is 0.40 and the average weighting 0.1%.

Quarter-by-quarter ownership
TWO SIGMA ADVISERS, LP ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$46,138
-34.0%
39,100
-21.2%
0.00%
Q2 2023$69,935
-30.5%
49,599
-26.1%
0.00%
Q1 2023$100,649
-3.5%
67,099
-24.7%
0.00%
Q4 2022$104,321
-58.1%
89,163
-59.5%
0.00%
-100.0%
Q3 2022$249,000
-40.1%
220,063
-16.3%
0.00%0.0%
Q2 2022$416,000
-56.1%
263,066
-57.3%
0.00%
-66.7%
Q1 2022$948,000
-64.5%
615,766
-43.5%
0.00%
-57.1%
Q4 2021$2,671,000
-4.7%
1,090,366
-2.0%
0.01%0.0%
Q3 2021$2,803,000
-46.1%
1,112,366
-39.0%
0.01%
-50.0%
Q2 2021$5,200,000
+35.4%
1,824,566
+11.7%
0.01%
+27.3%
Q1 2021$3,840,000
+328.1%
1,633,866
+220.5%
0.01%
+450.0%
Q4 2020$897,000
+183.9%
509,866
+51.0%
0.00%
+100.0%
Q3 2020$316,000
+24.4%
337,666
+15.7%
0.00%0.0%
Q2 2020$254,000
+31.6%
291,766
+24.9%
0.00%0.0%
Q1 2020$193,000
-11.9%
233,566
-5.2%
0.00%0.0%
Q4 2019$219,000
+19.0%
246,366
+31.1%
0.00%
Q3 2019$184,000187,9660.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders